BR8701121A
(pt)
|
1986-03-12 |
1988-01-05 |
Glaxo Group Ltd |
Processo para a preparacao de um composto e processo para combate a pestes
|
ES2113879T3
(es)
|
1990-01-24 |
1998-05-16 |
Douglas I Buckley |
Analogos de glp-1 utiles para el tratamiento de diabetes.
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
NZ265452A
(en)
|
1993-03-29 |
1997-09-22 |
Univ Cincinnati |
Analogues of peptide yy, dimers and pharmaceutical compositions
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
WO1995033474A1
(fr)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Composition medicinale
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
BR9604880A
(pt)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
JP3149958B2
(ja)
|
1996-08-30 |
2001-03-26 |
ノボ ノルディスク アクティーゼルスカブ |
Glp―1誘導体
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
ATE366584T1
(de)
|
1996-11-12 |
2007-08-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
EP1015007A1
(en)
|
1996-11-13 |
2000-07-05 |
The University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
WO1999043341A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
JP2002506792A
(ja)
|
1998-02-27 |
2002-03-05 |
ノボ ノルディスク アクティーゼルスカブ |
N末端修飾glp−1誘導体
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
DE69942306D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
CN1311773A
(zh)
|
1998-06-08 |
2001-09-05 |
先灵公司 |
神经肽y5受体拮抗剂
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
JP2002523333A
(ja)
|
1998-07-31 |
2002-07-30 |
ノボ ノルディスク アクティーゼルスカブ |
Ii型糖尿病を予防するためのglp−1及び類似体の利用
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
CZ295890B6
(cs)
|
1998-12-07 |
2005-11-16 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající kyselinu aminoizomáselnou pozici 8 a D-arginin na pozici 36, jejich použití a farmaceutické prostředky je obsahující
|
ATE309197T1
(de)
|
1999-02-05 |
2005-11-15 |
Emisphere Tech Inc |
Verfahren zur herstellung alkylierter salicylamide
|
JP2002537321A
(ja)
|
1999-02-22 |
2002-11-05 |
エラン コーポレイション ピーエルスィー |
促進剤を含む固体経口剤形
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
PT1180121E
(pt)
|
1999-05-17 |
2004-03-31 |
Conjuchem Inc |
Peptidos insulinotropicos de longa duracao
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
EP1355942B1
(en)
|
2000-12-07 |
2008-08-27 |
Eli Lilly And Company |
Glp-1 fusion proteins
|
US7199217B2
(en)
|
2000-12-13 |
2007-04-03 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
AU2002230843B8
(en)
|
2000-12-14 |
2007-05-17 |
Amylin Pharmaceuticals, Llc |
Peptide YY and peptide YY agonists for treatment of metabolic disorders
|
GB0102075D0
(en)
*
|
2001-01-26 |
2001-03-14 |
Astrazeneca Ab |
Process
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
US7576050B2
(en)
|
2001-07-31 |
2009-08-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US7459432B2
(en)
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
CA2466863A1
(en)
|
2001-11-29 |
2003-06-05 |
Emisphere Technologies, Inc. |
Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
EP1478347A1
(en)
|
2002-02-01 |
2004-11-24 |
Pfizer Products Inc. |
Dry granulated formulations of azithromycin
|
EP1478233B1
(en)
|
2002-02-20 |
2016-11-09 |
Emisphere Technologies, Inc. |
Method for administering glp-1 molecules
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
US7811989B2
(en)
|
2003-01-17 |
2010-10-12 |
Ipsen Pharma S.A.S. |
Peptide YY analogs
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
DK1605897T3
(da)
|
2003-03-19 |
2012-08-20 |
Lilly Co Eli |
Polyethelen-glycol-link-glp-1-forbindelser
|
US20050009748A1
(en)
|
2003-05-14 |
2005-01-13 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
US20070065505A1
(en)
|
2003-07-11 |
2007-03-22 |
Shoufeng Li |
Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
|
JP2007501811A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
|
JP4949838B2
(ja)
|
2003-09-19 |
2012-06-13 |
ノヴォ ノルディスク アー/エス |
新規glp−1誘導体
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
ES2660320T3
(es)
|
2003-11-20 |
2018-03-21 |
Novo Nordisk A/S |
Formulaciones peptídicas que contienen propilenglicol que son óptimas para la producción y para el uso en dispositivos de inyección
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
BRPI0417684A
(pt)
|
2003-12-18 |
2007-03-20 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
CA2849552A1
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
WO2005077094A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
CN100425282C
(zh)
|
2004-03-17 |
2008-10-15 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y2/y4选择性受体激动剂
|
BRPI0507585A
(pt)
|
2004-03-17 |
2007-07-03 |
7Tm Pharmas As |
agonistas seletivos do receptor y2 para intervenções terapêuticas
|
JP2007531714A
(ja)
|
2004-03-17 |
2007-11-08 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy2/y4選択性レセプターアゴニスト
|
EP2057996A3
(en)
|
2004-03-17 |
2009-11-04 |
7TM Pharma A/S |
Y4 selective receptor agonists for therapeutic intervention
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
CA2564866A1
(en)
|
2004-05-06 |
2005-11-17 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
CN102001963B
(zh)
|
2004-05-06 |
2014-04-16 |
爱密斯菲尔科技公司 |
N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
|
EP2279732B1
(en)
|
2004-05-14 |
2019-03-20 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
RU2006144821A
(ru)
|
2004-07-08 |
2008-08-20 |
Ново Нордиск А/С (DK) |
Пролонгирующие метки полипептидов, содержащие тетразольную группировку
|
BRPI0513101A
(pt)
|
2004-07-12 |
2008-04-29 |
Emisphere Tech Inc |
forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem
|
WO2006020207A2
(en)
|
2004-07-19 |
2006-02-23 |
University Of Cincinnati |
Compounds for control of appetite
|
WO2006124047A2
(en)
|
2004-08-13 |
2006-11-23 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
JP5175553B2
(ja)
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
胃内滞留および制御放出型送達系
|
JP4933455B2
(ja)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
新規のインスリン誘導体
|
CA2599723A1
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
BRPI0608516A2
(pt)
|
2005-03-18 |
2010-11-16 |
Novo Nordisk As |
análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
|
WO2006097536A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
CA2603105A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
PE20061448A1
(es)
|
2005-05-26 |
2006-12-17 |
Bristol Myers Squibb Co |
Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano
|
CA2614619A1
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
WO2007011958A2
(en)
|
2005-07-15 |
2007-01-25 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
EP1907010A2
(en)
|
2005-07-18 |
2008-04-09 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
RU2421237C2
(ru)
|
2005-08-19 |
2011-06-20 |
Амилин Фармасьютикалз, Инк. |
Способы лечения диабета и снижения массы тела
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
JP2009508886A
(ja)
|
2005-09-21 |
2009-03-05 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy2選択性レセプターアゴニスト
|
EP1934254A1
(en)
|
2005-09-21 |
2008-06-25 |
7TM Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
KR20140053419A
(ko)
|
2005-11-17 |
2014-05-07 |
노파르티스 아게 |
약제학적 조성물
|
JP5000663B2
(ja)
|
2005-12-07 |
2012-08-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
神経ペプチド2受容体アゴニスト
|
US20080318861A1
(en)
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
EP1963343A1
(en)
|
2005-12-14 |
2008-09-03 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
AU2007227202B2
(en)
|
2006-03-21 |
2013-08-22 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase inhibitor conjugates and methods of using same
|
US7704977B2
(en)
|
2006-04-07 |
2010-04-27 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
ES2548393T3
(es)
|
2006-05-09 |
2015-10-16 |
Novo Nordisk A/S |
Derivado de insulina
|
WO2007146234A2
(en)
|
2006-06-09 |
2007-12-21 |
Merrion Research Ii Limited |
Solid oral dosage form containing an enhancer
|
WO2008003050A2
(en)
|
2006-06-28 |
2008-01-03 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
KR101081149B1
(ko)
|
2006-09-07 |
2011-11-07 |
에미스페어 테크놀로지스, 인코포레이티드 |
Snac(살카프로제이트 나트륨)의 제조 방법
|
TWI430806B
(zh)
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
用於投與長效降血糖藥劑之方法
|
AR062925A1
(es)
|
2006-09-22 |
2008-12-17 |
Novartis Ag |
Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US20100022446A1
(en)
|
2007-01-18 |
2010-01-28 |
Novo Nordisk A/S |
Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
|
WO2008087186A2
(en)
|
2007-01-18 |
2008-07-24 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
KR20150091536A
(ko)
|
2007-03-02 |
2015-08-11 |
노파르티스 아게 |
칼시토닌의 경구 투여
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
EP2171080A4
(en)
|
2007-06-12 |
2010-10-27 |
Glaxosmithkline Llc |
METHODS OF PROTEIN DETECTION IN PLASMA
|
US8093689B2
(en)
*
|
2007-07-02 |
2012-01-10 |
Infineon Technologies Ag |
Attachment member for semiconductor sensor device
|
EP2322620A3
(en)
|
2007-07-09 |
2011-08-31 |
Imperial Innovations Ltd. |
Analogs of human pancreatic polypeptide and their effects on feeding behaviour
|
CN101842101A
(zh)
|
2007-08-29 |
2010-09-22 |
加利福尼亚大学董事会 |
水杨酰苯胺修饰的肽用作口服治疗剂
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
EP2190873B1
(en)
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
EP2187935A2
(en)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
UA114700C2
(uk)
|
2007-10-16 |
2017-07-25 |
Біокон Лімітед |
Тверда фармацевтична форма для перорального застосування та процес її виготовлення
|
RU2469728C2
(ru)
|
2007-11-02 |
2012-12-20 |
Эмисфире Текнолоджис, Инк. |
Способ лечения дефицита витамина b12
|
US20090124639A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
RU2504550C2
(ru)
|
2008-05-16 |
2014-01-20 |
Ново Нордиск А/С |
Длительно действующие агонисты рецепторов y2 и(или) y4
|
EP3741359A1
(en)
*
|
2008-08-18 |
2020-11-25 |
Entera Bio Ltd. |
Methods and compositions for oral administration of proteins
|
EP2340049B1
(en)
|
2008-09-12 |
2015-11-11 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
MY156811A
(en)
|
2008-10-15 |
2016-03-31 |
Bayer Corpscience Ag |
Use of dithiine-tetracarboximides for controlling phytopathogenic fungsi
|
CA2741921A1
(en)
|
2008-11-05 |
2010-05-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2-receptor (y-2r) agonists and uses thereof
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
KR20160143897A
(ko)
|
2009-02-13 |
2016-12-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Dpp-4 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
|
CN102325545A
(zh)
|
2009-02-20 |
2012-01-18 |
益普生制药股份有限公司 |
具有神经肽y受体结合化合物的细胞毒性缀合物
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
US20130040877A1
(en)
|
2009-09-18 |
2013-02-14 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
CN102596228A
(zh)
|
2009-10-13 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
神经肽-2受体(y-2r)激动剂
|
JP2013510829A
(ja)
|
2009-11-13 |
2013-03-28 |
ノヴォ ノルディスク アー/エス |
長時間作用型y2受容体アゴニスト
|
WO2011084618A2
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
MX2012006634A
(es)
|
2009-12-16 |
2012-06-21 |
Novo Nordisk As |
Derivados de peptidos tipo glucagon 1 de doble acilato.
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
WO2011116139A2
(en)
|
2010-03-16 |
2011-09-22 |
Chiasma Inc. |
Improved pharmaceutical compositions and methods of delivery
|
WO2011131646A1
(en)
|
2010-04-20 |
2011-10-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
RU2012151296A
(ru)
|
2010-04-30 |
2014-06-10 |
Санва Кагаку Кенкюсо Ко., Лтд |
Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность
|
CA2797310C
(en)
|
2010-05-05 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
JP5902194B2
(ja)
|
2010-12-16 |
2016-04-13 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストとn−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
AU2012241894B2
(en)
|
2011-04-12 |
2015-12-03 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
CN104271588B
(zh)
|
2011-07-08 |
2017-10-10 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
HRP20231060T1
(hr)
|
2012-03-22 |
2023-12-22 |
Novo Nordisk A/S |
Pripravci peptida glp-1 i njihova priprava
|
EP4331667A3
(en)
|
2012-03-22 |
2024-05-08 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
HUE042757T2
(hu)
|
2012-03-22 |
2019-07-29 |
Novo Nordisk As |
Szállító szert tartalmazó készítmények és elõállításuk
|
EP2855517A1
(en)
|
2012-05-29 |
2015-04-08 |
Novo Nordisk A/S |
Pancreatic polypeptide compounds and use
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
MX366405B
(es)
|
2012-07-01 |
2019-07-08 |
Novo Nordisk As |
Uso de peptidos glp-1 de accion prolongada.
|
AR096162A1
(es)
|
2013-05-02 |
2015-12-09 |
Glaxosmithkline Ip Dev Ltd |
Péptidos terapéuticos
|
KR102272671B1
(ko)
|
2013-05-02 |
2021-07-06 |
노보 노르디스크 에이/에스 |
Glp-1 화합물의 경구 투여
|
US10583172B2
(en)
|
2013-11-15 |
2020-03-10 |
Novo Nordisk A/S |
HPYY(1-36) having a beta-homoarginine substitution at position 35
|
SI3068421T1
(sl)
|
2013-11-15 |
2019-08-30 |
Novo Nordisk A/S |
Selektivne spojine PYY in njihova uporaba
|
US20180050096A1
(en)
|
2015-02-09 |
2018-02-22 |
Entera Bio Ltd. |
Treatment of hypoparathyroidism
|
RU2726777C2
(ru)
|
2015-06-12 |
2020-07-15 |
Ново Нордиск А/С |
Селективные соединения пептида yy и их применения
|
EP3359181A1
(en)
|
2015-10-07 |
2018-08-15 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
EP4299118A3
(en)
|
2018-02-02 |
2024-04-10 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|